Incyte Corporation (INCY) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Incyte Corporation (INCY) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Incyte Remains Undervalued As Opzelura And Niktimvo Scale
Incyte started 2026 on a high note. On January 7, its stock hit an all-time high of $112.29. In my view, the key drivers of raised investor interest in Incyte are the strong performance of its ruxolitinib franchise.
Incyte: Why The Market Is Overreacting To A Guidance 'Miss'
Incyte experienced an 8.2% sell-off after 2026 guidance appeared to miss consensus by $680M, but this was due to a royalties accounting nuance. Adjusted for royalties, INCY's 2026 sales guidance is nearly in line with expectations, representing 11.5% YoY growth in Net Product Sales. Opzelura sales guidance was slightly below consensus, but the ex-Jakafi portfolio is growing rapidly, supporting a robust long-term outlook.
Incyte Corporation (INCY) Q4 2025 Earnings Call Transcript
Incyte Corporation (INCY) Q4 2025 Earnings Call Transcript
INCY Q4 Earnings Miss Estimates, Revenues Beat on Higher Product Sales
Incyte posts a Q4 EPS miss but a 28% revenue jump, fueled by Jakafi and Opzelura strength, as product sales top estimates.
Incyte (INCY) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
While the top- and bottom-line numbers for Incyte (INCY) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Incyte (INCY) Q4 Earnings Lag Estimates
Incyte (INCY) came out with quarterly earnings of $1.8 per share, missing the Zacks Consensus Estimate of $1.94 per share. This compares to earnings of $1.43 per share a year ago.
Incyte weak 2026 revenue forecast heightens Jakafi patent concerns
Incyte forecast annual sales below Wall Street estimates on Tuesday with its key growth driver Opzelura expected to underperform, raising concerns about the drugmaker's ability to offset looming patent losses on top-seller Jakafi.
Here's Why Incyte (INCY) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Incyte Gears Up to Report Q4 Earnings: Is a Beat in the Cards?
INCY heads into Q4 earnings with strong Jakafi sales, rising royalties and multiple new launches contributing to revenues, setting the stage for a potential upside surprise.
Unveiling Incyte (INCY) Q4 Outlook: Wall Street Estimates for Key Metrics
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Incyte (INCY), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2025.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
